These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27155254)

  • 1. Dissolution and coarsening of polydisperse, polymorph drug particles liberated from a disintegrating finished dosage form: Theoretical considerations.
    Horkovics-Kovats S
    Eur J Pharm Sci; 2016 Aug; 91():265-77. PubMed ID: 27155254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. General solution for diffusion-controlled dissolution of spherical particles. 1. Theory.
    Wang J; Flanagan DR
    J Pharm Sci; 1999 Jul; 88(7):731-8. PubMed ID: 10393573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population data analysis of dissolution time profiles: Assessment of physicochemical properties of the drug, drug particles and the pharmaceutical formulation.
    Horkovics-Kovats S; Brunovský P; Pichler A; Bulitta JB
    Eur J Pharm Sci; 2015 Oct; 78():245-54. PubMed ID: 26215465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissolution kinetic behavior of drug nanoparticles and their conformity to the diffusion model.
    Heng D; Cutler DJ; Chan HK; Yun J; Raper JA
    Langmuir; 2008 Jul; 24(14):7538-44. PubMed ID: 18558778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical methods for dissolution testing of nanosized drugs.
    Jünemann D; Dressman J
    J Pharm Pharmacol; 2012 Jul; 64(7):931-43. PubMed ID: 22686341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of methods for predicting dissolution and the theoretical implications of particle-size-dependent solubility.
    Johnson KC
    J Pharm Sci; 2012 Feb; 101(2):681-9. PubMed ID: 21989679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disintegration rate and properties of active pharmaceutical ingredient particles as determined from the dissolution time profile of a pharmaceutical formulation: an inverse problem.
    Horkovics-Kovats S
    J Pharm Sci; 2014 Feb; 103(2):456-64. PubMed ID: 24338791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of nanosizing on solubility and dissolution rate of poorly soluble pharmaceuticals.
    Murdande SB; Shah DA; Dave RH
    J Pharm Sci; 2015 Jun; 104(6):2094-2102. PubMed ID: 25821105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth.
    Lindfors L; Skantze P; Skantze U; Westergren J; Olsson U
    Langmuir; 2007 Sep; 23(19):9866-74. PubMed ID: 17696457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental determination of the diffusion boundary layer width of micron and submicron particles.
    Galli C
    Int J Pharm; 2006 Apr; 313(1-2):114-22. PubMed ID: 16529883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals.
    Crisp MT; Tucker CJ; Rogers TL; Williams RO; Johnston KP
    J Control Release; 2007 Feb; 117(3):351-9. PubMed ID: 17239469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Diffusion-Controlled Dissolution from Polydisperse Collections of Drug Particles with an Assessed Mathematical Model.
    Wang Y; Abrahamsson B; Lindfors L; Brasseur JG
    J Pharm Sci; 2015 Sep; 104(9):2998-3017. PubMed ID: 25989144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissolution of irregularly-shaped drug particles: mathematical modelling.
    Abrami M; Grassi M; Masiello D; Pontrelli G
    Eur J Pharm Biopharm; 2022 Aug; 177():199-210. PubMed ID: 35772613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.
    Nekkanti V; Pillai R; Venkateshwarlu V; Harisudhan T
    Pharm Dev Technol; 2009; 14(3):290-8. PubMed ID: 19235553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanocrystal Dissolution Kinetics and Solubility Increase Prediction from Molecular Dynamics: The Case of α-, β-, and γ-Glycine.
    Parks C; Koswara A; Tung HH; Nere NK; Bordawekar S; Nagy ZK; Ramkrishna D
    Mol Pharm; 2017 Apr; 14(4):1023-1032. PubMed ID: 28271901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets.
    Lai F; Pini E; Angioni G; Manca ML; Perricci J; Sinico C; Fadda AM
    Eur J Pharm Biopharm; 2011 Nov; 79(3):552-8. PubMed ID: 21820052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ISD3: a particokinetic model for predicting the combined effects of particle sedimentation, diffusion and dissolution on cellular dosimetry for in vitro systems.
    Thomas DG; Smith JN; Thrall BD; Baer DR; Jolley H; Munusamy P; Kodali V; Demokritou P; Cohen J; Teeguarden JG
    Part Fibre Toxicol; 2018 Jan; 15(1):6. PubMed ID: 29368623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fast-dissolving microparticles fail to show improved oral bioavailability.
    Wong SM; Kellaway IW; Murdan S
    J Pharm Pharmacol; 2006 Oct; 58(10):1319-26. PubMed ID: 17034654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel mathematical model considering change of diffusion coefficient for predicting dissolution behavior of acetaminophen from wax matrix dosage form.
    Nitanai Y; Agata Y; Iwao Y; Itai S
    Int J Pharm; 2012 May; 428(1-2):82-90. PubMed ID: 22405986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new modelling approach for dissolution of polydisperse powders.
    van der Zwaan I; Frenning G
    Int J Pharm; 2023 Feb; 633():122626. PubMed ID: 36690125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.